Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1998 Nov;89(11):1229–1238. doi: 10.1111/j.1349-7006.1998.tb00519.x

A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA Complex

Mitsuharu Hanada 1, Satoko Mizuno 1, Akihisa Fukushima 1, Yoshikazu Saito 2, Toshihiro Noguchi 1, Takashi Yamaoka 1
PMCID: PMC5921721  PMID: 9914793

Abstract

Amrubicin is a novel, completely synthetic 9‐aminoanthracycline derivative. Amrubicin and its C‐13 alcohol metabolite, amrubicinol, inhibited purified human DNA topoisomerase II (topo II). Compared with doxorubicin (DXR), amrubicin and amrubicinol induced extensive DNA‐protein complex formation and double‐strand DNA breaks in CCRF‐CEM cells and KU‐2 cells. In this study, we found that ICRF‐193, a topo II catalytic inhibitor, antagonized both DNA‐protein complex formation and double‐strand DNA breaks induced by amrubicin and amrubicinol. Coordinately, cell growth inhibition induced by amrubicin and amrubicinol, but not that induced by DXR, was antagonized by ICRF‐193. Taken together, these findings indicate that the cell growth‐inhibitory effects of amrubicin and amrubicinol are due to DNA‐protein complex formation followed by double‐strand DNA breaks, which are mediated by topo II.

Keywords: Amrubicin, Anthracycline, DNA‐protein complex, Double‐strand DNA break, DNA topoisomerase II

Full Text

The Full Text of this article is available as a PDF (812.1 KB).

REFERENCES

  • 1. ) Wang , J. C.DNA topoisomerases . Annu. Rev. Biochem. , 54 , 665 – 697 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) D'Arpa , P. and Liu , L. F.Topoisomerase‐targeting antitumor drugs . Biochim. Biophys. Acta , 989 , 163 – 177 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Liu , L. F.DNA topoisomerase II poisons as antitumor drugs . Annu. Rev. Biochem. , 58 , 351 – 375 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Ishizumi , K. , Ohashi , N. and Tanno , N.Stereospecific total synthesis of 9‐aminoanthracyclines: (+)‐9‐amino‐9‐deoxydaunomycin and related compounds . J. Org. Chem. , 52 , 4477 – 4485 ( 1987. ). [Google Scholar]
  • 5. ) Morisada , S. , Yanagi , Y. , Noguchi , T. , Kashiwazaki , Y. and Fukui , M.Antitumor activities of a novel 9‐aminoan‐thracycline (SM‐5887) against mouse experimental tumors and human tumor xenografts . Jpn. J. Cancer Res. , 80 , 69 – 76 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. ) Inoue , K. , Ogawa , M. , Horikoshi , N. , Mukaiyama , T. , Itoh , Y. , Imajoh , K. , Ozeki , H. , Nagamine , D. and Shinagawa , K.Phase I study of SM‐5887, a new anthracycline derivative . Jpn. J. Cancer Chemother. , 18 , 1771 – 1776 ( 1988. ). [PubMed] [Google Scholar]
  • 7. ) Kuffel , M. J. , Reid , J. M. and Ames , M. M.Anthracyclines and their C‐13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture . Cancer Chemother. Pharmacol. , 30 , 51 – 57 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Suzuki , T. , Arai , M. , Iwasaki , T. , Yamamoto , H. and Kanda , H.The cardiotoxicity of a new anthracycline, SM‐5887, in rabbits . Proc. Jpn. Cancer Assoc.46th Annu. Meet. , 447 ( 1987. ). [Google Scholar]
  • 9. ) Yana , T. , Negoro , S. , Takada , Y. , Yokota , S. , Fukuoka , M. and the West Japan Lung Cancer Group . Phase II study of amrubicin (SM‐5887), a novel 9‐amino‐anthracycline, in previously untreated patients with extensive stage small‐cell lung cancer (ES‐SCLC): a West Japan Lung Cancer Group trial . American Society of Clinical Oncology 34th Annual Meeting , 1734 ( 1998. ).
  • 10. ) Hiraki , S. , Shinkai , T. , Furuse , K. , Fukuoka , M. , Ohnoshi , T. , Kimura , I. and the SM‐5887 Lung Cancer Study Group . A phase II of SM‐5887, a novel 9‐aminoanthracycline, for non‐small cell lung cancer . 18th International Congress of Chemotherapy , 726A ( 1993. ).
  • 11. ) Tanabe , K. , Ikegami , Y. , Ishida , R. and Andoh , T.Inhibition of topoisomerase II by antitumor agents bis(2,6‐dioxypiperazine) derivatives . Cancer Res. , 51 , 4903 – 4908 ( 1991. ). [PubMed] [Google Scholar]
  • 12. ) Creighton , A. M.Piperazine derivatives having anticancer activity . GB 1234935 ; Chem. Abstr. , 75 , 140889 ( 1971. ). [Google Scholar]
  • 13. ) Chooi , S. Y. M. , Leung , P. , Ng , S. , Quek , G. H. and Sim , K. Y.A simple route to optically pure 2,3‐diaminobutane . Tetrahedron: Asymmetry , 2 , 981 – 982 ( 1991. ). [Google Scholar]
  • 14. ) Terasaki , T. , Iga , T. , Sugiyama , Y. and Hanano , M.Interaction of doxorubicin with nuclei isolated from rat liver and kidney . J. Pharm. Sci. , 73 , 524 – 528 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Ono , K. , Ikegami , Y. , Wierzba , K. , Yamada , Y. and Andoh , T.Mechanism of inhibition of DNA topoisomerases activity by TUT‐7, an antitumor antibiotic . Proc. Jpn. Cancer Assoc. 49th Annu. Meet. , 2075 ( 1990. ). [Google Scholar]
  • 16. ) Chen , M. and Beck , W. T.Teniposide‐resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non‐complex stabilizing inhibitors of the enzyme, display no cross‐resistance and reveal aberrant functions of the mutant enzyme . Cancer Res. , 53 , 5946 – 5953 ( 1993. ). [PubMed] [Google Scholar]
  • 17. ) Rowe , T. C. , Chen , G. L. , Hsiang , Y. H. and Liu , L. F.DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II . Cancer Res. , 46 , 2021 – 2026 ( 1986. ). [PubMed] [Google Scholar]
  • 18. ) Wolverton , J. S. , Danks , M. K. , Granzen , B. and Beck , W. T.DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors . Cancer Res. , 52 , 4248 – 4253 ( 1992. ). [PubMed] [Google Scholar]
  • 19. ) Waring , M. J.DNA modification and cancer . Annu. Rev. Biochem. , 50 , 159 – 192 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Capranico , G. , Zunino , F. , Kohn , K. W. and Pommier , Y.Sequence‐selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity . Biochemistry , 29 , 562 – 569 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Chen , G. L. , Yang , L. , Rowe , T. C. , Halligan , B. D. , Tewey , K. and Liu , L. F.Nonintercalative antitumor drugs interfere with the breakage‐reunion reaction of mammalian DNA topoisomerase II . J. Biol. Chem. , 259 , 13560 – 13566 ( 1984. ). [PubMed] [Google Scholar]
  • 22. ) Tewey , K. M. , Chen , G. L. , Nelson , E. M. and Liu , L. F.Intercalative antitumor drugs interfere with the breakage‐reunion reaction of mammalian DNA topoisomerase II . J. Biol. Chem. , 259 , 9182 – 9187 ( 1984. ). [PubMed] [Google Scholar]
  • 23. ) Tewey , K. M. , Rowe , T. C. , Yang , L. , Halligan , B. D. and Liu , L. F.Adriamycin‐induced DNA damage mediated by mammalian DNA topoisomerase II . Science , 226 , 466 – 468 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Drake , F. H. , Hofmann , G. A. , Mong , S. M. , Bartus , J. O. , Hertzberg , R. , Johnson , R. K. , Mattern , M. R. and Mirabelli , C. K.In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone . Cancer Res. , 49 , 2578 – 2583 ( 1989. ). [PubMed] [Google Scholar]
  • 25. ) Sørensen , B. S. , Sinding , J. , Andersen , A. H. , Alsner , J. , Jensen , P. B. and Westergaard , O.Mode of action of topoisomerase II‐targeting agents at a specific DNA sequence . J. Mol. Biol. , 228 , 778 – 786 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Bojanowski , K. , Lelievre , S. , Markovits , J. , Couprie , J. , Jacquemin‐Sablon , A. and Larsen , A. K.Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells . Proc. Natl. Acad. Sci. USA , 89 , 3025 – 3029 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. ) Boritzki , T. J. , Wolfard , T. S. , Besserer , J. A. , Jackson , R. C. and Fry , D. W.Inhibition of type II topoisomerase by fostriecin . Biochem. Pharmacol. , 37 , 4063 – 4068 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Jensen , P. B. , Sørensen , B. S. , Demant , E. J. F. , Sehested , M. , Jensen . P. S. , Vindeløv , L. and Hansen , H. H.Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′‐(9‐acridinylamino) methanesulfon‐m‐anisidine in human small cell lung cancer cell lines and topoisomerase II‐mediated DNA cleavage . Cancer Res. , 50 , 3311 – 3316 ( 1990. ). [PubMed] [Google Scholar]
  • 29. ) Jensen , P. B. , Jensen P. S. , Demant , E. J. F. , Friche , E. , Sørensen , B. S. , Sehested , M. , Wassermann , K. , Vindeløv , L. , Westergaad , O. and Hansen , H. H.Antagonistic effect of aclarubicin on daunorubicin‐induced in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II . Cancer Res. , 51 , 5093 – 5099 ( 1991. ). [PubMed] [Google Scholar]
  • 30. ) Roca , J. , Ishida , R. , Berger , J. M. , Andoh , T. and Wang , J. C.Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp . Proc. Natl. Acad. Sci. USA , 91 , 1781 – 1785 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. ) Ishida , R. , Miki , T. , Narita , T. , Yui , R. , Sato , M. , Utsumi , K. R. , Tanabe , K. and Andoh , T.Inhibition of intracellular topoisomerase II by antitumor bis(2,6‐dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex‐forming type inhibitors . Cancer Res. , 51 , 4909 – 4916 ( 1991. ). [PubMed] [Google Scholar]
  • 32. ) Long , B. H. , Musial , S. T. and Brattain , M. G.Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16‐213 and VM26: a quantitative structure‐activity relationship . Biochemistry , 23 , 1183 – 1188 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Keiser , H. G. , Pinedo , H. M. , Schuurhuis , G. J. and Joenje , H.Doxorubicin (adriamycin): a critical review of free radical‐dependent mechanisms of cytotoxicity . Pharmacol. Ther. , 47 , 219 – 231 ( 1990. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES